SciBase receives additional order from Castle Biosciences, advancing the collaboration

SciBase secures a $0.6 million Nevisense Go order from Castle Biosciences to speed an ongoing AD study and prepare a second trial.

Rhea-AI Summary

SciBase Holding (SCIB) and Castle Biosciences (CSTL) expanded their collaboration as SciBase received an additional order worth about $0.6 million (≈MSEK 5) for its Nevisense Go pen devices and electrodes to support Castle's atopic dermatitis research.

The order will accelerate the ongoing clinical study aimed at predicting relapses in atopic dermatitis and fund preparations for a second clinical study under the existing collaboration and license agreement signed in 2025. Deliveries of the ordered devices and electrodes are expected to begin in Q4 2026. SciBase characterizes this order as a signal of collaboration expansion, supported by rapid patient recruitment in the first joint study.

Positive

• Additional order value around $0.6 million (≈MSEK 5) for Nevisense Go and electrodes
• Deliveries from Q4 2026 to accelerate first AD study and prepare a second study

Negative

• None.

Market Context

CSTL was up 0.8% pre-headline, while four of five listed peers also gained, so the additional Castle...

Analysis

CSTL was up 0.8% pre-headline, while four of five listed peers also gained, so the additional Castle collaboration order arrived amid aligned diagnostic-sector trading.

Key Figures

Additional order value: $0.6 million / MSEK 5 Expected deliveries: Q4 2026

Additional order value

$0.6 million / MSEK 5

Nevisense Go device and electrodes

Expected deliveries

Q4 2026

Additional Castle Biosciences order

Key Terms

atopic dermatitis, molecular diagnostics, point-of-care

3 terms

atopic dermatitis medical

"which aims to predict relapses in atopic dermatitis (AD)"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

molecular diagnostics medical

"a US-based leader in molecular diagnostics"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

point-of-care medical

"Nevisense, a unique point-of-care platform"

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.

In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration project, which aims to predict relapses in atopic dermatitis (AD), is ongoing and this order is for both an acceleration of the initial clinical study as well as preparation for a second clinical study. Deliveries are expected to start in Q4 2026.

"The collaboration with Castle Biosciences is moving forward at a fast pace with rapid patient recruitment in our first joint study and this additional order signals the expansion of our collaboration," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 03:00 PM CEST on September 8, 2026.

About SciBase  
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases  

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-receives-additional-order-from-castle-biosciences--advancing-the-collaboration,c4393402

The following files are available for download:

https://mb.cision.com/Main/12371/4393402/4258029.pdf

PR order 2 Castle eng

 

View original content:https://www.prnewswire.com/news-releases/scibase-receives-additional-order-from-castle-biosciences-advancing-the-collaboration-302872356.html

SOURCE SciBase

FAQ

What is the purpose of the new order from Castle Biosciences?

The order is intended to both accelerate the current clinical study under the SciBase–Castle collaboration, which aims to predict relapses in atopic dermatitis, and to support preparations for a second clinical study in the same collaboration framework.

When are the Nevisense Go devices and electrodes scheduled to be delivered?

Deliveries of the ordered Nevisense Go pen devices and electrodes are expected to start in Q4 2026.

What technology is SciBase supplying for these studies?

SciBase is supplying its portable Nevisense Go pen device and electrodes, part of the Nevisense platform that combines AI and electrical impedance spectroscopy (EIS) to support improved diagnostic accuracy in dermatology.